New drug cocktail shows promise in shrinking pancreatic tumors before surgery
NCT ID NCT04940286
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two chemotherapy drugs and two immunotherapy drugs given before surgery to people with pancreatic cancer that can be removed. The goal is to shrink the tumor and help the immune system fight the cancer, potentially improving outcomes. The trial involves 13 participants and focuses on how well the tumor responds and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Could a Decades-Old parasite drug help fight pancreatic cancer?
- Timing of chemo may boost survival in pancreatic cancer
- Could a common blood pressure pill boost radiation against tough pancreatic tumors?
- New chemo cocktail shows promise for pancreatic cancer patients before surgery
- New hope for pancreatic cancer: drug combo aims to shrink tumors before surgery